Results 131 to 140 of about 48,471 (314)

From Suspicion to Diagnosis: Analysis on the Clinical Characteristics of 37 Cases of IgG4-Related Disease (IgG4-RD) in Northeast China

open access: yesJournal of Inflammation Research, 2022
Shanshan Zhang, Jun Zhang, Yifang Li, Jian Jiao Department of Gastroenterology & Hepatology, China-Japan Union Hospital, Jilin University, Changchun, People’s Republic of ChinaCorrespondence: Jian Jiao, Email jjian@jlu.edu.cnIntroduction: IgG4-related ...
Zhang S, Zhang J, Li Y, Jiao J
doaj  

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

open access: yesCancer Science, EarlyView.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto   +20 more
wiley   +1 more source

IgG4-related disease as a variable-vessel vasculitis: A case series of 13 patients with medium-sized coronary artery involvement [PDF]

open access: green, 2023
Guy Katz   +9 more
openalex   +1 more source

Sutimlimab in Patients With Cold Agglutinin Disease (CAD): Results From a Managed Access Program

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a low‐grade lymphoproliferative disorder accounting for 15%–30% of patients suffering from autoimmune hemolytic anemias. The clonal B cells produce autoantibodies primarily of the IgM‐κ class that cause agglutination of red blood cells (RBCs) at temperatures ≤ 37°C and activate the classical complement pathway ...
Sandra Maria Frey   +5 more
wiley   +1 more source

IgG4-related disease

open access: diamond, 2020
Animesh Ray, Sujay Halkur Shankar
openalex   +1 more source

Genetic Determinants of Peanut‐Specific IgG4 Levels in the Context of Sustained Oral Peanut Exposure in the LEAP Study

open access: yesImmunology, EarlyView.
A cumulative genetic score based on IgG4‐associated variants explains a substantial proportion of variance in psIgG4 levels during sustained peanut consumption, highlighting strong gene‐by‐environment interactions. Our findings suggest that early, sustained peanut consumption, in combination with genetic factors, promotes a protective immune response ...
Kanika Kanchan   +14 more
wiley   +1 more source

Retroperitoneal fibrosis: a case of a patient (63y/o) treated with low-dose methotrexate (MTX) and 6-methylprednisolone (6-MP) [PDF]

open access: yes, 2018
Retroperitoneal fibrosis (RPF), is a rare fibroinflammatory disease. The pathogenesis of RPF is still unclear and numerous theories have been reported such as environmental factors, immunologic process, genetic component, local inflammation and advanced
A. Santoro   +6 more
core  

Home - About - Disclaimer - Privacy